My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe ...

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...

Another male patient with blood cancer had been administered approximately twice the prescribed dose of Fludarabine, another chemotherapy drug, for three consecutive days. In early March ...

Here are the critical medicines in short supply in the EU, according to the latest available information from the EMA and ...

Q4 2024 Earnings Call Transcript March 13, 2025 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...

Multiparametric quantitative MRI could potentially help differentiate between Duchenne muscular dystrophy and Becker muscular dystrophy early and improve the management of these conditions.

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.

The following is a summary of "BCL-2 dependence is a favorable predictive marker of response to therapy for chronic ...

Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab.

Patients were randomly assigned to receive acalabrutinib-venetoclax, acalabrutinib-venetoclax-obinutuzumab, or chemoimmunotherapy with the investigator's choice of fludarabine-cyclophosphamide ...